Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class (Alpha Blocker, 5- Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others), and Therapy (Mono Drug Therapy and Combination Drug Therapy) - Global Opportunity Analysis and Industry Forecast, 2018-2025
- Published Date: 2020-10-18
- Report ID: 3109
- Pages: 205
-
Format:
The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. This increase blocks the urine flow from the bladder, which results in increased urination frequency at night, urinary hesitancy, and urinary retention. BPH significantly influences the patients quality of life, owing to symptoms, such as urine leakage and nocturia. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs).
The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients. However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
The global benign prostatic hyperplasia therapeutics market is segmented into therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. As per therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).
KEY BENEFITS
The study provides an in-depth analysis of the global benign prostatic hyperplasia therapeutics market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
A comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
The profiles of key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key market segments
By Therapeutic Class
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
By Therapy
Mono drug therapy
Combination drug therapy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Allergan plc
Astellas Pharma, Inc.
Boehringer Ingelheim Pharma GmbH & Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Limited
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porters Five Forces analysis
3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer
3.5.2. Restraints
3.5.2.1. High preferences for minimally invasive surgical therapies
3.5.3. Opportunities
3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies
3.5.4. Impact analyses
3.6. Clinical trials
CHAPTER 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Alpha Blockers
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. 5-Alpha Reductase Inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Phosphodiesterase 5 Inhibitor
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY
5.1. Overview
5.1.1. Market size and forecast
5.2. Mono Drug Therapy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Combination Drug Therapy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America benign prostatic hyperplasia therapeutics market, by country
6.2.2.1. U.S.
6.2.2.1.1. Market size and forecast, by therapeutic class
6.2.2.1.2. Market size and forecast, by therapy
6.2.2.2. Canada
6.2.2.2.1. Market size and forecast, by therapeutic class
6.2.2.2.2. Market size and forecast, by therapy
6.2.2.3. Mexico
6.2.2.3.1. Market size and forecast, by therapeutic class
6.2.2.3.2. Market size and forecast, by therapy
6.2.3. North America market size and forecast, by therapeutic class
6.2.4. North America market size and forecast, by therapy
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Market size and forecast, by therapeutic class
6.3.2.1.2. Market size and forecast, by therapy
6.3.2.2. France
6.3.2.2.1. Market size and forecast, by therapeutic class
6.3.2.2.2. Market size and forecast, by therapy
6.3.2.3. UK
6.3.2.3.1. Market size and forecast, by therapeutic class
6.3.2.3.2. Market size and forecast, by therapy
6.3.2.4. Italy
6.3.2.4.1. Market size and forecast, by therapeutic class
6.3.2.4.2. Market size and forecast, by therapy
6.3.2.5. Spain
6.3.2.5.1. Market size and forecast, by therapeutic class
6.3.2.5.2. Market size and forecast, by therapy
6.3.3. Rest of Europe
6.3.3.1.1. Market size and forecast, by therapeutic class
6.3.3.1.2. Market size and forecast, by therapy
6.3.4. Europe market size and forecast, by therapeutic class
6.3.5. Europe market size and forecast, by therapy
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Market size and forecast, by therapeutic class
6.4.2.1.2. Market size and forecast, by therapy
6.4.2.2. China
6.4.2.2.1. Market size and forecast, by therapeutic class
6.4.2.2.2. Market size and forecast, by therapy
6.4.2.3. India
6.4.2.3.1. Market size and forecast, by therapeutic class
6.4.2.3.2. Market size and forecast, by therapy
6.4.2.4. Australia
6.4.2.4.1. Market size and forecast, by therapeutic class
6.4.2.4.2. Market size and forecast, by therapy
6.4.2.5. South Korea
6.4.2.5.1. Market size and forecast, by therapeutic class
6.4.2.5.2. Market size and forecast, by therapy
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Market size and forecast, by therapeutic class
6.4.2.6.2. Market size and forecast, by therapy
6.4.3. Asia-Pacific market size and forecast, by therapeutic class
6.4.4. Asia-Pacific market size and forecast, by therapy
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Market size and forecast, by therapeutic class
6.5.2.1.2. Market size and forecast, by therapy
6.5.2.2. Saudi Arabia
6.5.2.2.1. Market size and forecast, by therapeutic class
6.5.2.2.2. Market size and forecast, by therapy
6.5.2.3. South Africa
6.5.2.3.1. Market size and forecast, by therapeutic class
6.5.2.3.2. Market size and forecast, by therapy
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Market size and forecast, by therapeutic class
6.5.2.4.2. Market size and forecast, by therapy
6.5.3. LAMEA market size and forecast, by therapeutic class
6.5.4. LAMEA market size and forecast, by therapy
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. Allergan plc
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. Astellas Pharma Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. Boehringer Ingelheim Pharma GmbH & Co. KG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. GlaxoSmithKline plc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Pfizer Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.9. Sanofi
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
